<DOC>
	<DOC>NCT00272961</DOC>
	<brief_summary>The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.</brief_summary>
	<brief_title>A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.</brief_title>
	<detailed_description>The study was stopped due to Pfizer (sponsor) decision that the compound would not be involved in any further clinical development for the indication of resistant hypertension on 05 August 2008. This decision was not based on any safety or efficacy concern.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide</mesh_term>
	<criteria>Diagnosis of resistant hypertension. A stable antihypertensive drug regimen for at least 30 days. Sustained blood pressure greater than or equal to 180/120 mmHg. Required use of thigh cuff for blood pressure readings. Uncontrolled diabetes mellitus.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>